The oral GLP-1 race keeps adding competitors, and this month one of the quieter ones stepped up with a full Phase 2 readout. VCT220, an oral nonpeptide GLP-1 receptor agonist developed in China, was the subject of a randomized, double-blind, placebo-controlled Phase 2 trial published in Signal Transduction and Targeted Therapy on 14 August 2026.
If the name is unfamiliar, that is the point. Most of the community attention this year has gone to injectable compounds like retatrutide and the oral race between Eli Lilly and Novo Nordisk. VCT220 is part of the second wave: oral small molecules coming out of China that are trying to replicate what orforglipron did, without the peptide backbone.
What the Trial Did
The trial ran across 13 sites in China and enrolled 250 adults aged 18 to 75. Participants were either overweight (BMI 24-28 with at least one comorbidity) or had obesity (BMI of 28 or higher). They were randomised 3:1 to receive once-daily VCT220 or placebo for 16 weeks, alongside lifestyle counselling.
VCT220 was tested at three doses (80 mg, 120 mg, and 160 mg) with either slow or fast titration. The primary endpoint was percentage change in body weight from baseline to week 16.
The trial registration numbers are public: CTR20233978 in the Chinese registry and NCT06569355 on ClinicalTrials.gov.
The Results
At 16 weeks, mean body weight decreased by 5.75% on the 80 mg dose and up to 9.73% on the 160 mg fast-titration dose, compared with 1.61% in the placebo group. All doses were statistically significant against placebo.
The responder analysis is where the numbers get interesting. The proportion of participants achieving at least 5% weight loss ranged from 55.4% on 80 mg to 90.3% on 160 mg, versus 13.1% on placebo.
VCT220 also produced improvements in HbA1c, fasting insulin, and blood pressure over the 16 weeks. Adverse events were mostly mild to moderate gastrointestinal effects, most common during titration, and rarely led to discontinuation.
Why “Nonpeptide” Matters
VCT220 is not a peptide at all. It is a small molecule that activates the same GLP-1 receptor. That is the same design philosophy as orforglipron, the Eli Lilly oral GLP-1 that became the first FDA-approved oral in its class when it launched as Foundayo in April 2026.
The appeal of nonpeptide agonists is practical. Peptide-based GLP-1 drugs generally need to be injected, and oral versions of peptides have historically struggled with bioavailability. Small molecules can be designed for oral delivery from the start, which removes both the injection and the absorption problem in one move.
The tradeoff is potency relative to the injectable peptides. Nine to ten percent weight loss at 16 weeks is solid for an oral, but it is not retatrutide territory. The comparison that matters is against other orals, and the data so far looks competitive.
China’s GLP-1 Wave
VCT220 comes from the same ecosystem that has produced a flood of Chinese obesity candidates over the past two years. Companies like Kailera and Hengrui have been advancing their own oral and injectable GLP-1 assets, several with partnerships into Western markets.
The interesting structural point is speed. Chinese sponsors have been running large, multi-site trials quickly, and the quality of the published Phase 2 data has been improving. Signal Transduction and Targeted Therapy is a legitimate peer-reviewed journal, and the trial design here is conventional and well executed.
What the Research Says
The honest reading of this data is that it is early but real. Sixteen weeks is a short window, and the full weight-loss trajectory of VCT220 will only show in longer trials. The 90.3% responder rate on the higher dose is eye-catching, but responder rates at 16 weeks tend to compress as everyone catches up by week 52.
What matters for the broader landscape is that the oral nonpeptide GLP-1 category now has multiple credible players. Orforglipron has approval and launch data. Several Chinese candidates including VCT220 are accumulating Phase 2 and Phase 3 evidence. The oral GLP-1 field that looked like a two-horse race a year ago is becoming a crowd.
For the research community, the compound is worth watching as a data point in the ongoing comparison between injectable peptides and oral small molecules. The mechanisms are different, the delivery is different, and the outcomes will diverge in ways that will be interesting to track.
If you want to follow the oral GLP-1 conversation, we have covered the broader oral race in our piece on the oral GLP-1 contenders and the Foundayo launch and Medicare context. The retatrutide explainer covers the injectable triple agonist that remains the benchmark for the class. The Telegram community has been discussing the oral vs injectable tradeoff as the data comes in.
Sources
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.